Just Price for PCSK9 Inhibitors: No less, No More

Just Price for PCSK9 Inhibitors: No less, No More

See Article by Ko et al.

Bibliographic Details
Main Author:	Khurram Nasir
Format:	Article
Language:	English
Published:	Wiley 2018-11-01
Series:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:	Editorials atherosclerosis low‐density lipoprotein cholesterol outcome PCSK9
Online Access:	https://www.ahajournals.org/doi/10.1161/JAHA.118.010884

Similar Items

RETRACTED ARTICLE: Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2019-12-01)

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
by: K. O. Shnaider, et al.
Published: (2023-12-01)

Insight into the Evolving Role of PCSK9
by: Mateusz Maligłówka, et al.
Published: (2022-03-01)

PCSK9 as an Atherothrombotic Risk Factor
by: Tadeja Sotler, et al.
Published: (2023-01-01)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
by: Dennis T. Ko, et al.
Published: (2018-11-01)

The Concentration of PCSK9-Lp(a) Complexes and the Level of Blood Monocytes in Males with Coronary Atherosclerosis
by: Anastasiia Yu. Filatova, et al.
Published: (2023-06-01)

A Systematic Approach to Assess the Activity and Classification of PCSK9 Variants
by: Kepa B. Uribe, et al.
Published: (2021-12-01)

Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation
by: Christopher LaFratte, et al.
Published: (2023-09-01)

Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren
by: Yara Azar, et al.
Published: (2022-05-01)

Correlation of PCSK9 and Serum sdLDL Levels and Other Demographic and Laboratory Indicators in Healthy Individuals
by: Reza Hosseini-Fard, et al.
Published: (2018-05-01)

PCSK9 - A New and Potent Approach to Lowering Cholesterol
by: Thomas F. Whayne Jr.
Published: (2013-05-01)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
by: Piotr Pęczek, et al.
Published: (2021-05-01)

Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies
by: Giovanni Ciccarelli, et al.
Published: (2018-03-01)

The role of proprotein convertase subtilisin-kexin type 9 (PCSK9) in the vascular aging process – is there a link?
by: Malwina Grobelna, et al.
Published: (2019-10-01)

Role of PCSK9 in Homocysteine-Accelerated Lipid Accumulation in Macrophages and Atherosclerosis in ApoE−/− Mice
by: Ping Jin, et al.
Published: (2021-10-01)

PCSK9 variation and association with blood pressure in African Americans: preliminary findings from the HyperGEN and REGARDS studies
by: Ngan T Tran, et al.
Published: (2015-04-01)

Lipid-lowering treatment in the improvement of outcomes in patients with atherosclerotic cardiovascular disease and diabetes mellitus: the role of PCSK9 inhibitors
by: G. R. Galstyan, et al.
Published: (2018-12-01)

PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
by: Sai Sahana Sundararaman, et al.
Published: (2021-07-01)

PCSK9 Inhibitor causes a decrease in the level of oxidatively modified low-density lipoproteins in patients with coronary artery diseases
by: V Z Lankin, et al.
Published: (2018-09-01)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with PCSK9/LDLR pathway.
by: Sarina Ataei, et al.
Published: (2023-01-01)

PCSK9 inhibitors for acute coronary syndrome: the era of early implementation
by: Hongzhen Chen, et al.
Published: (2023-05-01)

Functional Crosstalk between PCSK9 Internalization and Pro-Inflammatory Activation in Human Macrophages: Role of Reactive Oxygen Species Release
by: Rafael I. Jaén, et al.
Published: (2022-08-01)

Impact of bariatric surgery on circulating PCSK9 levels as a marker of cardiovascular disease risk: a meta-analysis
by: Tannaz Jamialahmadi, et al.
Published: (2022-08-01)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
by: Aureli Luquero, et al.
Published: (2021-03-01)

Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis
by: A. Yu. Filatova, et al.
Published: (2019-06-01)

Lipid lowering: PCSK9 inhibitors – new kids on the block target their breakthrough
by: Markus Mohaupt
Published: (2016-07-01)

Targeting Allosteric Site of PCSK9 Enzyme for the Identification of Small Molecule Inhibitors: An In Silico Drug Repurposing Study
by: Nitin Bharat Charbe, et al.
Published: (2024-01-01)

Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation
by: Minglu Ma, et al.
Published: (2023-03-01)

Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors
by: Tina Levstek, et al.
Published: (2023-03-01)

Naturally Occurring PCSK9 Inhibitors
by: Maria Pia Adorni, et al.
Published: (2020-05-01)

PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
by: Julius L. Katzmann, et al.
Published: (2020-11-01)

PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)
by: Saeideh Sobati, et al.
Published: (2020-08-01)

Feasibility of Short-Term Aggressive Lipid-Lowering Therapy with the PCSK9 Antibody in Acute Coronary Syndrome
by: Satoshi Yamashita, et al.
Published: (2023-05-01)

Increased Circulating Levels of PCSK9 and Pro-Atherogenic Lipoprotein Profile in Pregnant Women with Maternal Supraphysiological Hypercholesterolemia
by: Claudette Cantin, et al.
Published: (2022-04-01)

PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2021-03-01)

Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis
by: Emily Punch, et al.
Published: (2022-02-01)

Impact of early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with acute coronary syndrome: A systematic review meta-analysis
by: Lakshmi Nagendra, et al.
Published: (2023-11-01)

PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma
by: Silvano Fasolato, et al.
Published: (2020-09-01)

Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice
by: Jean-Mathieu Berger, et al.
Published: (2017-08-01)

PCSK9 concentrations in different stages of subclinical atherosclerosis and their relationship with inflammation
by: Tóth Štefan, et al.
Published: (2020-08-01)